Wheel Balanced Cancer Therapy for Longer Than 21 Days Can Have a Positive Effect on the Survival of Patients with Stage IV Cancer

  • Jeon, Hyung-Joon (East West Cancer Center, Dunsan Korean Medicine Hospital of Daejeon University) ;
  • Kim, Jong-min (East West Cancer Center, Dunsan Korean Medicine Hospital of Daejeon University) ;
  • Cho, Chong-kwan (East West Cancer Center, Dunsan Korean Medicine Hospital of Daejeon University) ;
  • Lee, Yeon-weol (East West Cancer Center, Dunsan Korean Medicine Hospital of Daejeon University) ;
  • Yoo, Hwa-seung (East West Cancer Center, Dunsan Korean Medicine Hospital of Daejeon University)
  • Received : 2015.04.15
  • Accepted : 2015.05.29
  • Published : 2015.09.30


Objectives: Correlations of the levels of the nonspecific inflammatory markers C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) and of the coagulation marker fibrinogen with the treatment period of wheel balanced cancer therapy were determined. Methods: Electronic charts of stage IV cancer patients hospitalized from February 1, 2008, to November 30, 2013, were reviewed retrospectively. Patients whose laboratory follow-up tests included at least two data points for at least one marker were included. Patients receiving chemotherapy or radiotherapy or having Eastern Cooperative Oncology Group (ECOG) levels exceeding 2 were excluded. Correlations of the markers with the length of treatment for treatment periods ${\geq}21$ and ${\leq}20$ days were determined by gender and whether or not surgery had been performed. Results: Analyses of the CRP and the ESR revealed a higher proportion of patients with stable marker levels than with increased or decreased levels. Also, only the ESR in female and the CRP in male groups had higher proportions of patients with stable marker levels than with increased or decreased levels. The ${\geq}21$ day group had a higher proportion of patients with stable CRP and ESR levels than the ${\leq}20$ days group. Only the ESR in female and the CRP in male groups had higher proportions of patients with stable marker levels in the ${\geq}21$ day than in the ${\leq}20$ day group. In addition, only the CRP in the surgery group and the ESR in the non-surgery group had higher proportions of patients with stable marker levels in the ${\geq}21$ day group than in the ${\leq}20$ day group. Conclusion: For stage IV cancer patients at hospitals that offer Korean medicine, more than 21 days of long-term wheel balanced cancer therapy (WBCT) should help maintain the CRP and the ESR levels and should have a favorable effect on the survival rate.


  1. Kim DK, Oh SY, Kwon HC, Lee S, Kwon KA, Kim BG, et al. Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer. BMC Cancer. 2009;20(9):155-63.
  2. Maltoni M, Caraceni A, Brunelli C, Broeckaert B, Christakis N, Eychmueller S, et al. Prognostic factors in advanced cancer patients: evidence-based clinical recommendations-a study by the steering committee of the European association for palliative care. J Clin Oncol. 2005;23(25):6240-8.
  3. Nozoe T, Matsumata T, Kitamura M, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg. 1998;176(4):335-8.
  4. Ford ES. Leukocyte count, erythrocyte sedimentation rate, and diabetes incidence in a national sample of US adults. Am J Epidemiol. 2002;155(1):57-64.
  5. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119(1):15-22.
  6. Sengupta S, Lohse CM, Cheville JC, Leibovich BC, Thompson RH, Webster WS, et al. The preoperative erythrocyte sedimentation rate is an independent prognostic factor in renal cell carcinoma. Cancer. 2006;106(2):304-12.
  7. Johansson J, Sigurdsson T, Holmberg L, Bergstrom R. Erythrocyte sedimentation rate as a tumor marker in human prostatic cancer. an analysis of prognostic factors in 300 population-based consecutive cases. Cancer. 1992;70(6):1556-63.<1556::AID-CNCR2820700619>3.0.CO;2-I
  8. Encan T, Hannisdal E. Blood analyses as prognostic factors in primary lung cancer. Acta Oncol. 1990;29(2):151-4.
  9. Fibrinogen: MedlinePlus Medical Encyclopedia [Internet]. USA: Medline Plus; 2013 [cited on 2014 October 24]. Available from:
  10. Palumbo JS, Kombrinck KW, Drew AF, Grimes TS, Kiser JH, Degen JL, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood. 2000;96(10):3302-9.
  11. Shu X, McCulloch M, Xiao H, Broffman M, Gao J. Chinese herbal medicine and chemotherapy in the treatment of hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Integr Cancer Ther. 2005;4(3):219-29.
  12. Ning SY, Jiang BP, Xu L, Fang TH, Wu MH. Effect of liangxuehuayu recipe on hemorheology in rats with blood stasis syndrome. Asian Pac J Trop Med. 2012;5(12):935-8.
  13. Liu L, Duan JA, Tang Y, Guo J, Yang N, Ma H, et al. Taoren–Honghua herb pair and its main components promoting blood circulation through influencing on hemorheology, plasma coagulation and platelet aggregation. J Ethnopharmacol. 2012;139(2):381-7.
  14. Yoon JW, Cho CK, Shin JE, Yoo HS. Changes in the laboratory data for cancer patients treated with Korean-medicine-based Inpatient care. J Pharmacopuncture. 2014;17(1):20-6.
  15. Walsh D, Mahmoud F, Barna B. Assessment of nutritional status and prognosis in advanced cancer: interleukin-6, C-reactive protein, and the prognostic and inflammatory nutritional index. Support Care Cancer. 2003;11(1):60-2.
  16. Scott HR, McMillan DC, Forrest LM, Brown DJ, Mcardle CS, Milroy R. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer. 2002;87(3):264-7.
  17. Barber MD, Ross JA, Fearon KC. Changes in nutritional, functional, and inflammatory markers in advanced pancreatic cancer. Nutr Cancer. 1999;35(2):106-10.
  18. Hefler LA, Concin N, Hofstetter G, Marth C, Mustea A, Sehouli J, et al. Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res. 2008;14(3):710-4.
  19. Kodama J, Miyagi Y, Seki N, Tokumo K, Yoshinouchi M, Kobashi Y, et al. Serum C-reactive protein as a prognostic factor in patients with epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 1999;82(1):107-10.
  20. Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, Wener MH, et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol. 2009;27(21):3437-44.
  21. Crumley AB, McMillan DC, McKernan M, Going JJ, Shearer CJ, Stuart RC. An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer. Br J Cancer. 2006;94(11):1568-71.
  22. Nozoe T, Saeki H, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. AM J Surg. 2001;182(2):197-201.
  23. Hashimoto K, Ikeda Y, Korenaga D, Tanoue K, Hamatake M, Kawasaki K, et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer. 2005;103(9):1856-64.
  24. McMillan DC, Elahi MM, Sattar N, Angerson WJ, Johnstone J, McArdle CS. Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutr Cancer. 2001;41(1-2):64-9.
  25. Monreal M, Lafoz E, Casals A, Inaraja L, Montserrat E, Callejas JM, et al. Occult cancer in patients with deep venous thrombosis. a systematic approach. Cancer. 1991;67(2):541-5.<541::AID-CNCR2820670237>3.0.CO;2-J
  26. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood. 2005;105(1):178-85.
  27. Tang L, Liu K, Wang J, Wang C, Zhao P, Liu J. High preoperative plasma fibrinogen levels are associated with distant metastases and impaired prognosis after curative resection in patients with colorectal cancer. J Surg Oncol. 2010;102(5):428-32.
  28. Seebacher V, Polterauer S, Grimm C, Husslein H, Leipold H, Hefler-Frischmuth K, et al. The prognostic value of plasma fibrinogen levels in patients with endometrial cancer: a multi-centre trial. Br J Cancer. 2010;102(6):952-6.
  29. Polterauer S, Grimm C, Seebacher V, Concin N, Marth C, Tomovski C, et al. Plasma fibrinogen levels and prognosis in patients with ovarian cancer: a multicenter study. Oncologist. 2009;14(10):979-85.
  30. Robertson JFR, Pearson D, Price MR, Selby C, Pearson J, Blamey RW, et al. Prospective assessment of the role of five tumour markers in breast cancer. Cancer Immunol Immunother.1991;33(6):403-10.
  31. Henry-Amar M, Friedman S, Hayat M, Somers R, Meerwaldt JH, Carde P, et al. Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease. Ann Intern Med. 1991;114(5):361-5.
  32. Fossa SD, Kramar A, Droz JP. Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha. Eur J Cancer. 1994;30(9):1310-4.
  33. Gislason T, Nou E. Sedimentation rate, leucocytes, platelet count and haemoglobin in bronchial carcinoma:an epidemiological study. Eur J Respir Dis. 1985;66(2):141-6.
  34. Alexandrakis MG, Passam FH, Ganotakis ES, Sfiridaki K, Xilouri I, Perisinakis K, et al. The clinical and prognostic significance of erythrocyte sedimentation rate (ESR), serum interleukin-6 (IL-6) and acute phase protein levels in multiple myeloma. Clin Lab Haematol. 2003;25(1):41-6.
  35. Park HM, Kim SY, Jung IC, Lee YW, Cho CK, Yoo HS. Integrative tumor board: a case report and discussion from East-West cancer center. Integr Cancer Ther. 2010;9(2):236-45.
  36. Husain TM, Kim DH. C-reactive protein and erythrocyte sedimentation rate in orthopaedics. Univ of Penn Ortho Journal. 2002;15:13-6.

Cited by

  1. Correlation Between Natural Killer Cell Activity and Systemic Inflammatory Markers for Heterogeneous Cancer Patients Treated With Wheel Balance Cancer Therapy 2017,